Citations

Clear

4207 citation(s) found for "Chen, Yu".

Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma
Pfitzer, Jeremiah , Kumar, Shaji, Ness, Brian Van, Waliagha, Razan S. , Baughn, Linda B. , Keeton, Adam B. , Chen, Xi , Maxuitenko, Yulia Y. , Kumar, Shaji , Piazza, Gary Anthony , Mitra, Amit

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3263-3263

10.1182/blood-2024-207683 Get It

Mutations in genes that code for RAS isozymes (N- and K-) are the most common (40-50%) somatic variations in multiple myeloma (MM). While ~46% of patients with newly diagnosed MM carry a RAS/Raf mutation, >64% of patients with refractory/relapsed MM carry these mutations. RAS activation can also occur from upstream signaling through receptor tyrosine kinases (RTK) or loss-of-function mutations in GTPase-activating proteins (GAPs), which are prevalent in MM. Although covalent inhibitors targeting KRAS alleles are in various stages of clinical development, multiple mechanisms of resistance have been reported. We discovered and developed a novel, highly potent, and selective pan-RAS inhibitor, ADT-007, capable of suppressing MAPK/AKT signaling by blocking GTP activation of RAS. Here, we show that ADT-007 is effective against MM, particularly those MM cell lines harboring KRAS and NRAS mutations that are representative of relapsed/refractory myeloma (RRMM). For these studies, we compiled a panel of over 50 human myeloma cell lines (HMCLs) with broad biological and genetic heterogeneity that represent innate drug-response/resistance (refractory disease), as well as 10 pairs of parental and clonally-derived proteasome inhibitor (PI)- and immunomodulatory drug (IMD)- resistant HMCLs as models of acquired resistance (relapse). Using CRISPR-cas-directed gene editing, we also have generated clonal NRAS and KRAS mutants of drug-sensitive myeloma lines that initially had two wild-type alleles. All cell lines have been authenticated using the GenePrint 24 System and tested for mycoplasma contamination. First, we performed predictive analysis using single-cell RNA sequencing (scRNAseq; 10X Genomics) on all MM cell lines and demonstrated the potential efficacy of ADT-007 based on the subclonal expression of the target genes/pathways. Using in vitro chemosensitivity assays, ADT-007 was highly potent and effective in killing chemo-resistant and RAS-mutant myeloma cells as a single agent with IC50 values ranging from 0.76 to 12 nM with synergistic benefits if combined with PIs and IMDs. Combination indices (CI) were found to be consistently below 0.9, indicating a synergistic drug interaction. (Drug synergy was determined by CalcuSyn software based on Chou-Talalay's CI method and the isobologram algorithm). Caspase 3/7 assay and flow cytometry (Annexin V-FITC + propidium iodide) confirmed apoptosis induction by ADT-007. Furthermore, the in vitro efficacy of ADT-007 was significantly better (nM vs. µM IC50) than cyclorasin B4-27, a bicyclic peptidyl that has been reported as a potent pan-RAS inhibitor against several other cancers, and RMC-6236, a multi-selective noncovalent RAS(on) inhibitor which is in clinical trial for patients with advanced solid tumors harboring G12X, G13X, and Q61X mutations. Pre-vs-post-treatment bulk-RNA sequencing followed by pathway analysis (using Ingenuity Pathway Analysis and Gene Set Enrichment Analysis) showed that ADT-007 suppressed KRAS and NRAS in a dose-dependent manner. Immunoblotting analysis confirmed the dose-dependent reduction of protein markers implicated in cell survival and chemotherapeutic resistance in myeloma, including c-myc, Ki-67, NFkB, IRF4, IKZF1 (Ikaros) and IKZF3 (Aiolos). Finally, we performed pre-vs-post-treatment single-cell transcriptomics analysis, which revealed a distinct shift in clusters representing myeloma single-cell subpopulations following ADT-007 treatment. High-dimensional mass cytometry (cytometry by time of flight or CyTOF) analysis using heavy metal-conjugated proteins in RRMM patient bone marrow-derived primary myeloma cells is currently underway to confirm the cytotoxic effect of ADT-007 ex vivo. ADT-1004 is an orally bioavailable prodrug of ADT-007 designed to improve water solubility and metabolic stability. ADT-1004 has shown strong antitumor activity in highly aggressive and clinically relevant mouse models of pancreatic cancer at dosages, is well tolerated, and is being developed by the NCI Stepping Stones program. Next, we plan to evaluate the antitumor activity of ADT-1004 in mouse xenograft models of human myeloma using immunocompromised mice. Our research will lay the groundwork for future development efforts needed to advance ADT-1004 to clinical trials involving patients with RRMM.
Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
Hung, Kevin , Price, Zoe, Al‐Kali, Aref , Ladon, Dariusz, Begna, Kebede H. , Rud, Danielle, Litzow, Mark R. , Bardy, Peter, Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Yi, Cecilia Y. Arana , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Hung, Kevin , Shah, Meera , Baranwal, Anmol , Toop, Carla , Greipp, Patricia T. , Brown, Anna , Chen, Dong , Kutyna, Monika , Hogan, William J. , Badar, Talha , Kumar, Sharad , Yeung, David , Scott, Hamish S. , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Hahn, Christopher N , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow , Hiwase, Devendra

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3213-3213

10.1182/blood-2024-198269 Get It

Background: TP53-mutated (TP53mut) myeloid neoplasms (MN) have particularly poor survival. Discrepancies in defining TP53mut MN have impact on diagnostic work up, therapeutic decisions, and clinical trial enrolment. Methods: MN cases harboring TP53mut (variant allele frequency, VAF ≥2%) were classified based on bone marrow (BM) and peripheral blood (PB) blast % using the 4th revision of the WHO classification (WHO-4R). Biallelic loss was defined as (i) ≥2 mutations each with VAF ≥2%; (ii) single TP53mut VAF ≥2% plus 17p loss detected on karyotype, FISH, or SNP; or (iii) single TP53mut VAF ≥50%, whereas monoallelic loss was defined as single TP53mut VAF <50% without 17p loss. Primary endpoint was overall survival (OS) from diagnosis. Conditional Inference Trees (CIT) analysis was used to determine the true effect of a predictor. Results: We identified 580 cases including WHO-4R defined acute myeloid leukemia (AML, BM/PB blasts ≥20%, n=219, 37.8%), myelodysplastic syndrome (MDS) with excess blasts-2 (EB-2, BM 10-19% or PB 5%-19%, n=92, 15.9%), MDS with excess blasts-1 (EB-1, BM 5-9% or PB 2-4%, n=75, 12.9%), and the remaining were MDS with low blasts (-LB, BM <5% and PB ≤1%, n=194, 33.4%). Of the 578 cases evaluable for allelic status, 437 (75.6%) and 141 (24.4%) had biallelic and monoallelic TP53 loss, respectively. Higher frequency of biallelic loss was observed with increasing blasts. 63.2%, 73.3%, 78% and 86.3% of cases with MDS-LB, MDS-EB1, MDS-EB2, and AML had bi-allelic TP53 loss (P<0.0001). In a multivariable analysis, WHO-4R categories, VAF ≥10%, and biallelic loss were independent predictors of poor survival. CIT analysis further stratified the cohort into 4 groups with distinct survival: (1) MDS-LB (n=194, 33.4%); (2) MDS-EB1/EB2 and AML with VAF <10% (n=38, 6.6%); (3) MDS-EB1/EB2 with VAF ≥10% (n=149, 25.7%); and (4) AML with VAF ≥10% (n=199, 34.3%). MDS-LB cases could be further stratified based on allelic status and complex karyotype (CK): OS was poor for cases with biallelic TP53 loss and monoallelic TP53mut with CK compared to monoallelic TP53mut without CK, who had the most favorable survival (12.7 vs. 13 vs. 34.8 months, P<0.0001).MDS-EB1/EB2/AML with VAF<10% could also be stratified by CK: MDS-EB1/EB2/AML with VAF<10% cases without CK had the favorable survival compared to their counterparts with CK and MDS-EB1/EB2 with VAF ≥10% cases (26.2 vs. 5.6 vs. 6.3 months, P=0.003).MDS-EB1/EB2 with VAF ≥10% was a homogenous subgroup: Biological characteristics including the proportion of cases with biallelic TP53 loss, CK (P>0.9), monosomal karyotype (MK, P>0.9), del 5q (P=0.6), del 7q (P=0.4), and del 17p (P=0.2) were comparable between MDS-EB1 and -EB2 with VAF ≥10%. Importantly, median OS of MDS-EB1 and EB2 with VAF ≥10% was comparable (9.6 vs. 7.2 months, P=0.12). OS in this group was comparable regardless of the blast %, allelic status, or presence of CK.AML with VAF ≥10% had extremely poor survival: Median OS was 3.9 months. Survival of AML was equally poor irrespective of the mono- or biallelic (3.6 vs. 3.9, P=0.89) and non-CK vs. CK (1.8 vs. 3.9 months, P=0.09). Combined, our model would acknowledge poor survival of 514 (89.1%) cases. In contrast, retrospective application of the 5th edition of the WHO classification (WHO-5) and International Consensus Classification (ICC) would classify only 211 (36.4%) and 468 (80.7%) cases as biallelic/multi-hit TP53mut MN, respectively. Finally, the Harrell's c-index of the proposed model, WHO-5, and ICC was 0.66, 0.571, and 0.617, respectively. Conclusion: We provide evidence for subsequent refinements in classifying MN harboring TP53mut. Our salient findings include: (i) acknowledgement of CK as ‘biallelic equivalent’ in MDS-LB; as well as EB1/EB2/AML with VAF 2 to <10% cases; and (ii) demonstration of poor survival of MDS-EB1 and -EB2 with VAF ≥10% regardless of the allelic status. In conclusion, our proposed model acknowledged poor survival of a higher proportion of cases as TP53mut MN compared to the current models with a higher c- index.
Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
Annunzio, Kaitlin , Karimi, Yasmin , Luu, Binh, Spurgeon, Stephen E. , Chang, Cheryl , Wan, Zihan, Gathers, Diamone, King, Emily R., Gerhard, Genevieve M. , Armand, Philippe , LaCasce, Ann S. , Vaddaraju, Vedha, Kenkre, Vaishalee P. , Junge, Chase, Stanisic, Alexander V., Zhang, Chen , Ying, Grace W, Gribbin, Caitlin , Ruan, Jia , Shukla, Navika , Smith, Sonali M. , Zelikson, Viktoriya, Williams, Michael, Elghawy, Omar , Schade, Jake , Navalekar, Rohini, Evens, Andrew M. , Danilov, Alexey V. , Fenske, Timothy S. , Stanisic, Alexander , Karimi, Yasmin H , Evens, Andrew M , Stanisic, Alexander V , Wang, Jie , Zhou, Jihao , Wang, Yucai , Muñoz, Javier , Shim, Kevin G. , Moustafa, Muhamad Alhaj , Baidoun, Firas , Epperla, Narendranath , McLane, Michael, Luu, Binh, King, Emily R., Watkins, Marcus P. , Bartlett, Nancy L. , Ryan, Christine E. , Vaddaraju, Vedha , Wallace, Danielle , Junge, Chase, Grover, Natalie S. , Florindez, Jorge A. , Karmali, Reem , Venugopal, Parameswaran , Barta, Stefan K , Matasar, Matthew J.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4406-4406

10.1182/blood-2024-194601 Get It

Introduction: Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) Prognosis is highly variable due to underlying biological and molecular heterogeneity. The first-line (1L) treatment paradigm for MCL continues to evolve with increasing use of bruton tyrosine kinase inhibitors (BTKi) and decreasing use of autologous stem cell transplant (ASCT). TP53 alterations are associated with inferior outcomes in MCL. The aim of this retrospective study is to determine treatment strategies and clinical outcomes in MCL patients based on TP53 gene mutation status. Methods: Retrospective data were collected from 19 institutions in the United States from 1/1993 to 1/2024. We examined treatment patterns and outcomes among MCL patients >18 years of age with known TP53 mutation status by sequencing. Patients who did not receive treatment were excluded. The analysis was stratified based on presence of TP53 mutations. Systemic therapies were categorized as chemo-immunotherapy (CIT), non-chemotherapy (including monoclonal antibodies, lenalidomide, venetoclax, and novel agents on clinical trial), and regimens containing BTKi. The primary outcome was overall survival (OS) and secondary outcomes were progression free survival (PFS) and time to next treatment (TTNT). OS and PFS were estimated with the Kaplan-Meier method and log-rank tests were used to compare groups. Results: 645 patients were included in the study, with 468 men (72.6%) and median age was 64 years (range 30-89). 230/645 patients (35.7%) had a TP53 mutation, of which 182 (79%) were identified prior to 1L. While the male/female distribution was the same between the mutated and unmutated groups, median age at diagnosis and MIPI risk score was higher in the TP53 mutated group (age 65.9 vs 63.1 yrs, p= 0.015; MIPI 6.4 vs 6.1, p<0.001). TP53 unmutated patients had a median of 1 line of therapy vs. 2 for the mutated group (p<0.001, range 1-8). Blastoid histology and higher ki67 were also associated with the TP53 mutated group (p=0.045, 0.01 respectively) The median OS was 14.2 years for TP53 unmutated and 8.3 years for TP53 mutated patients (p<0.0001). PFS in 1L was 0.95 years in TP53 mutated compared to 2.02 years in TP53 unmutated group (p<0.0001). Selection of 1L therapeutic strategy was not associated with presence of TP53 mutation (Χ2 p= 0.21) although more patients in the TP53 unmutated group underwent ASCT (119/415 vs 38/230; Χ2 p=0.0006) TP53 mutation was associated with inferior survival compared to TP53 unmutated patients for CIT in 1L but the difference did not reach statistical significance when non-chemotherapy regimens and regimens containing BTKi were used. For CIT in 1L, 5 year OS was 78% [71-84%] for unmutated compared to 58% [48-67%] for the mutated group (p=0.0001 ). For non-chemotherapy regimens, 5 year OS for unmutated patients was 73% [52- 86%] compared to 52% [25-73%] for the mutated group (p=0.09). For regimens containing BTKi, 5 year OS for unmutated was 93% [81-97%] compared to 57% [28-78%] for mutated (p=0.07). Within the TP53 mutated group, there were no differences in any clinical outcomes between those receiving CIT, non-chemotherapy, or BTKi in 1L. While median OS appeared numerically longer in the BTKi group (14.4 yrs vs 8.8 yrs for CIT and 6.8 yrs for non-chemotherapy), the difference did not reach statistical significance (p=0.58). In contrast,TP53 unmutated patients who received CIT in 1L had better TTNT (p=0.0039) compared to those in non-chemotherapy and BTKi groups. There was no improvement in PFS (p=0.79) or OS (p=0.47). Conclusions To our knowledge this is the largest retrospective real world dataset of MCL treatment outcomes stratified by TP53 mutation. As in prior studies, TP53 mutation portends a worse prognosis in MCL compared to TP53 unmutated patients, but outcomes are better than historically reported. CIT in 1L was not associated with improved OS in either group. Irrespective of TP53 mutation status, incorporation of BTKi in first line was not associated with improved clinical outcomes. The gap in OS between TP53 mutated and unmutated MCL may be narrowing as treatment paradigms shift away from intensive induction chemotherapy and ASCT, and due to an increasing number of effective therapies for relapsed patients. Clinical trials of novel agents are needed to further improve the OS of TP53 mutated MCL patients.
Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
Kumar, Anupama, Hashmi, Hamza , Corraes, Andre De Menezes Silva , Htut, Myo, Scheller, Lukas , Kadel, Sofie‐Katrin , Hájek, Roman , Martínez‐López, Joaquín , Biran, Noa , Abrahamsen, Ingerid Weum , Chen, Szu-Ying, Ng, Melissa , Harrison, Simon J, Costello, Caitlin , Matos, Isadora, Gupta, Sasha , Lin, Yi, Hajek, Roman , Martinez-Lopez, Joaquin , Abrahamsen, Ingerid Weum , Atallah‐Yunes, Suheil Albert , Rajeeve, Sridevi , Abdelhak, Ahmed , Htut, Myo , Rodríguez‐Otero, Paula , Parrondo, Ricardo D , Chhabra, Saurabh , Kortüm, K. Martin , Einsele, Hermann , Donk, Niels W.C.J. van de , Mihalyova, Jana , Larrea, Carlos Fernández de , Chen, Szu‐Ying , Patiño-Escobar, Bonell , Harrison, Simon J , Matos, Isadora, Crusoé, Edvan de Queiroz , Costa, Luciano J. , Wiita, Arun P. , Martin, Thomas G. , Chari, Ajai

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4758-4758

10.1182/blood-2024-201783 Get It

Background Emerging evidence has demonstrated rare subacute to late neurological toxicities (NTs) after BCMA CAR T-cell therapy (CAR-T) in multiple myeloma (MM). These adverse events can be categorized as: 1) Parkinsonism (PD), 2) cranial nerve (CN) palsies, and 3) peripheral neuropathies/Guillan Barré syndrome (GBS). These toxicities can cause significant morbidity, but given their relative rarity in clinical trials, there is limited data regarding evaluation and treatment. To our knowledge, this is the largest and only global registry of delayed NTs after BCMA CAR-T. Methods We retrospectively established a registry of NTs via the Immune Therapy Working Committee of the International Myeloma Working Group (IMWG). We gathered data pertaining to demographics, MM characteristics, MM response, NT signs/symptoms, diagnostic workup, and treatment. Result A total of 52 patients with delayed neurotoxicity were included from 14 institutions and 6 countries; 92% received ciltacel, 4% idecel, and 4% investigational CAR-T. Median age at CAR-T infusion was 65 years; 69% were male and 88% were Caucasian. Median bone marrow plasma cell (PC) burden was 15% prior to CAR-T (range 0-95%). Patients received a median of 4 prior lines of therapy (LOT), with 67% progressing on last LOT. Seventeen percent had pre-existing neurological diagnoses (including stroke, epilepsy, migraines). We identified sixteen cases of PD (94% with movement disorder, 69% with cognitive impairment, 75% with personality changes), occurring at a median of 26 days (range: 15-87) after CAR-T. Ninety four percent had CRS (grade (G)1 50%, G2 38%, G3 6%, G4 0%), while 19% had ICANS (G1 13%, G2 6%, G3-G4 0%). Median peak absolute lymphocyte count (ALC) was 9.5 x 109/L, peak C-reactive protein (CRP) 60.9 mg/L, and peak ferritin 1893.5 ug/L within the first 30 days. Concurrently, 3 upper respiratory infections (URIs) and 2 low-level HHV7 in the cerebrospinal fluid (CSF) were detected. A median of 73% of T-cells in the CSF were CAR-T, based on a flow cytometry assay. Ten patients received steroids (median 19 days after symptoms, 70% partial response, 20% no response, 10% unknown), 2 received intrathecal (IT) methotrexate-based therapy (median 32 days after symptoms, 1 with no response, 1 unknown), 5 received intravenous (IV) cyclophosphamide (median 31 days after symptoms, 40% full response, 20% partial response, 40% no response), 4 received high-dose IVIG ≥1g/kg for one or more dose (50% partial response, 50% no response), and 6 received dopamine agonists. There were 37 CN palsies (76% CN7, 15% CN6, 7% CN5, 2% CN3), occurring at a median of 37.5 days (range: 7-482) after CAR-T. Eighty one percent had CRS (G1 68%, G2 14%, G3-G4 0%); 11% had G1 ICANS (G2-G4 0%). Median peak ALC was 4.1 x 109/L, CRP 25.4 mg/L, and ferritin 543 ug/L within the first 30 days. We identified 2 concurrent URIs, 4 CMV viremia (50% with viral load >1500 IU/mL), 1 HHV6 viremia, and 1 HSV in the CSF. Thirty-two (86%) received steroids for a median duration of 12 days, 50% with full response, 3% with no response, and 47% with partial response (of which 43% had later full recovery without further intervention). One received IT methotrexate and another received IV cyclophosphamide without response. Thirteen (41%) received IVIG, of which 38% was high-dose IVIG. Four patients with CN palsies developed peripheral neuropathy/GBS. Eight patients (15%) in this cohort were not heavily pre-treated (≤1 prior LOT); 7 developed CN palsies (6 after ciltacel, 1 after investigational CAR-T) and 1 PD (after idecel). These patients had median <5% PC; none had extramedullary disease. Median ALC was 4.14 x 109/L, CRP 33 mg/L, and ferritin 448.5 ug/L within the first 30 days. Conclusions Delayed NT requires prompt recognition, evaluation for alternative causes, and treatment. In our cohort, the majority of patients were male and Caucasian, suggesting that sex and race may impact the likelihood of developing NT. Individuals with PDs had greater inflammatory response (CRS, ALC, CRP, ferritin) compared to those with CN palsies. CN palsies responded to steroids and/or IVIG, whereas PD had at best partial response to steroids, prompting additional therapy. These toxicities notably did occur in less heavily pre-treated patients, perhaps driven by immune fitness and greater circulating T-cells rather than MM burden. At the time of the annual meeting, data will be updated with additional NTs from less heavily pre-treated patients.
BCL2 Expression Correlates with New Molecular Classification of Anaplastic Large Cell Lymphoma
Gimenez, J. , Jiang, Liuyan , Salama, Farah M., Chapman‐Fredricks, Jennifer R., Chen, Weina , Sidhu, Jagmohan S. , Wu, Xiaojun , Ansell, Stephen M. , Hu, Guangzhen , Gimenez, Jimena B., Shi, Min , Oishi, Naoki , Feldman, Andrew L.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4381-4381

10.1182/blood-2024-208516 Get It

Background: Anaplastic large cell lymphomas represent a group of T-cell lymphomas that have long been broadly classified by the presence or absence of ALK fusion proteins (ALK+ or ALK−, respectively). However, recent discovery of extensive additional molecular heterogeneity has both promoted refinement of disease classification and uncovered new opportunities for biomarker-guided targeted therapy. In addition to recognition of a new genetic subtype, ALK− ALCL with DUSP22 rearrangement (R), a new molecular classification has been proposed based on the recent discovery of 2 overarching molecular types of ALCL, defined by the presence (Type I) or absence (Type II) of a gene expression signature highly enriched for JAK-STAT3 activation. BCL2 is a mitochondrial membrane protein that functions to inhibit the actions of pro-apoptotic proteins such as BAX and BAK and can be targeted clinically by BCL2 small molecule inhibitors. BCL2 has been reported to be expressed more frequently in ALK− ALCL than in ALK+ ALCL, but its expression in the context of current molecular findings is unknown. Methods: ALCLs were centrally reviewed and classified by current WHO/ICC criteria. BCL2 was performed using IHC and scored as positive if ≥30% of tumor cells showed staining. DUSP22-R was assessed by fluorescence in situ hybridization (FISH) using a breakapart probe set and a dual-color, dual-fusion (D) probe set for the most common DUSP22 translocation, t(6;7)(p25.3;q32.3). pSTAT3Y705 IHC, which is >90% accurate for Type I/II assignment based on gene expression, was performed and scored based on a previously validated cut-off of ≥30%. Results: We evaluated 217 ALCLs (148M/69F; age: mean, 57 y; range, 5-93 y), including 55 systemic ALK+ ALCLs, 127 systemic ALK− ALCLs, and 35 primary cutaneous (pc) ALCLs. Overall, 86/217 cases were positive for BCL2 (40%). BCL2 was positive in 67/127 ALK− ALCLs (53%) and 15/35 pcALCLs (43%; P=NS), but in only 4/51 ALK+ (7%; P<0.0001). DUSP22-R was present in 90 cases (63 ALK− ALCL and 27 pcALCL). BCL2 was positive in 57/90 cases with DUSP22-R (63%) compared to 29/127 without DUSP22-R (23%; P<0.0001). Among 85 cases with DUSP22-R and informative D-FISH testing, BCL2 was positive in 24/36 cases with t(6;7)(p25.3;q32.3) (67%) and 31/49 cases without t(6;7)(p25.3;q32.3) (63%; P=NS). Among 213 cases with informative pSTAT3Y705 staining, BCL2 was positive in 13/88 pSTAT3+ cases (Type I, 15%) and 70/125 pSTAT3− cases (Type II, 56%; P<0.0001). Conclusions: We identified a complex pattern of BCL2 expression across ALCLs that strongly correlates with a recently introduced molecular classification based on gene expression profiling. While our findings are in keeping with the previously reported low expression in ALK+ ALCL, we found that the higher expression in both systemic ALK− ALCL and pcALCL is particularly associated with DUSP22-R and the absence of pSTAT3Y705 expression (Type II ALCLs). The discovery of 2 overarching types of ALCL associated with the presence or absence JAK-STAT3 pathway activation represents a new conceptual framework for classifying ALCL and understanding its therapeutic vulnerabilities. Of note, previous data demonstrated that Type II ALCLs are enriched for epigenetic alterations and particularly overexpress the histone methyltransferase EZH2. Correlation between BCL2 expression and EZH2 expression also is observed in other lymphomas such as diffuse large B-cell lymphoma, where dual targeting with EZH2 and BCL2 inhibitors has been proposed. Thus, our findings provide further rationale for stratifying Type I and Type II ALCLs and identify BCL2 as a differentially expressed oncoprotein that might represent a target for precision therapy approaches.
Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Allan, John N. , Nowakowski, Grzegorz S. , Wang, A., Yu, Junhua, Sail, Kavita, Harb, Diala, Mutebi, Alex, Chhibber, Anindit, Elliot, Brian, Atiya, Mohammad, Thiéblemont, Catherine , Fox, Christopher P. , Riedell, Peter A. , Phillips, Tycel , Alshreef, Abualbishr , Chen, Cheng , Mutebi, Alex

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2349-2349

10.1182/blood-2024-203994 Get It

Background: Epcoritamab (epcor) is a first-in-class CD3xCD20 bispecific antibody (bsAb) approved for the treatment of 3L+ LBCL and follicular lymphoma. In the single-arm, phase 1/2, EPCORE NHL-1 trial (NCT03625037), epcor given until disease progression or unacceptable toxicity, demonstrated deep and durable responses, a median overall survival (OS) of 18.5 months, and a manageable safety profile in R/R LBCL. A second CD3xCD20 bsAb given as fixed-treatment duration, glofitamab (glofit), also demonstrated durable responses, conferring a median OS of 11.5 months in the pivotal study. Understanding how long-term outcomes compare among bsAb agents remains an important knowledge gap. With over 2 years of follow-up, in the absence of a head-to-head study, it is now relevant to compare the efficacy of these agents via indirect comparison. This study evaluated OS, progression-free survival (PFS), and duration of complete response (DoCR) of epcor vs glofit in R/R LBCL using data from the respective pivotal trials. Methods: Two analyses were conducted to compare the efficacy of epcor and glofit. First, a matching-adjusted indirect treatment comparison (MAIC) was conducted using published OS and PFS data from the full cohort of the glofit pivotal trial (12.6 months of follow-up, Dickinson et al, 2022) and the epcor pivotal trial (EPCORE NHL-1). Piece-wise hazard ratios (HRs) were calculated when proportional hazards assumptions were not met. Baseline characteristic prognostic variables were selected based on literature, clinical judgement, and empirical statistical testing and were adjusted between epcor and glofit cohorts. Second, in sensitivity analyses, indirect comparisons were conducted using an updated analysis of glofit with longer follow-up that included DoCR, together with OS and PFS data starting at cycle (C) 3 with 32 months of follow-up (Hutchings et al, ASH 2023). Sensitivity analyses with longer follow-up could not be adjusted because glofit pt baseline characteristics were not presented. Aggregate OS and PFS curves for glofit were derived from subgroups of pts with complete response/partial response/no response (CR/PR/NR) at C3 (Hutchings et al, ASH 2023). Aggregate epcor OS and PFS curves were similarly derived for pts with CR/PR/NR at C3 without prior disease progression. Weighted Cox proportional-hazards models were used to estimate the OS and PFS HRs between the 2 comparators. The DoCR comparison included all glofit and epcor pts achieving CR. All comparisons used EPCORE NHL-1 data with a median of 37.1 months of follow-up. Results: Pts enrolled into the pivotal trials of epcor and glofit were comparable by several key baseline characteristics before adjustment: age ≥65 y; male gender; Ann Arbor disease stage III-IV; primary refractory disease; refractory to most recent anti-CD20 therapy; previous chimeric antigen receptor T-cell therapy (CAR T); refractory to CAR T; and previous autologous stem cell transplant (ASCT). MAIC analysis revealed no significant difference in OS benefit from C1 until month 6 (HR 1.08, 95% CI 0.71, 1.64; P=0.72), but a demonstrable OS advantage from 6 months onward (HR 0.60, 95% CI 0.37, 0.98; P=0.04) in favor of epcor. An OS comparison starting at C3 with longer glofit follow-up demonstrated a consistent survival advantage in favor of epcor (HR 0.68, 95% CI 0.46, 1.01; P=0.05). The proportion of pts who received CAR T or ASCT subsequent therapy were similar for epcor and glofit (CAR T: 7.0% vs 8.9%; ASCT: 6.4% vs 6.3%) (National Institute for Health and Care Excellence Glofit Single Technology Appraisal, 2023). The MAIC analysis showed comparable PFS between epcor and glofit (HR 1.06, 95% CI 0.79, 1.41; P=0.71), although there was substantial censoring in the glofit PFS curve due to immature follow-up. With longer follow-up in the analysis starting at C3, with less censoring, the glofit PFS curve remained similar to the epcor PFS curve from C3 until month 6 (HR 0.67, 95% CI 0.42, 1.07; P=0.10), where separation of the PFS curves were observed favoring epcor (HR 0.56, 95% CI 0.33, 0.97; P=0.04). Median DoCR was longer for epcor (36.1 months) vs glofit (26.9 months). Conclusion: These indirect treatment comparisons suggest that epcor may provide an overall survival benefit over glofit through longer PFS with more mature follow-up, potentially driven by longer DoCR. Survival data with longer follow-up in the full glofit cohort are needed to confirm these findings.
Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis
Brakhane, Molly , Buduo, Christian A. Di , Sadler, Brooke , Ashworth, Katrina , Kong, Tim , Fulbright, Mary C., Pegoraro, Elena , Gollomp, Kandace , Abbonante, Vittorio , Laranjeira, Angelo B. A. , He, Fan , Chen, Dong , Clemens, Regina A. , Lambert, Michele P. , Paola, Jorge Di , Balduini, Alessandra , Oh, Stephen T.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1169-1169

10.1182/blood-2024-210283 Get It

Activating mutations in the calcium sensor STIM1 underlie Stormorken Syndrome (SS), a rare congenital disorder that causes thrombocytopenia and tubular aggregate myopathy. We recently identified two patients with SS and confirmed mutations in STIM1 (R304W and S88G), who were found to have features consistent with myelofibrosis (MF), as indicated by bone marrow biopsies demonstrating megakaryocyte hyperplasia and atypia in conjunction with marked reticulin fibrosis. The unusual MF findings in these two patients raised the hypothesis that altered calcium signaling represents a shared hallmark of congenital platelet disorders such as Stormorken Syndrome and myeloproliferative neoplasms (MPNs) including MF. Analyzing gene expression data from public datasets, we found increased expression of STIM1 in megakaryocyte progenitors and platelets, as well as CD34+ hematopoietic stem/progenitor cells (HSPCs), from MPN patients (including those with CALR or JAK2 mutations) vs healthy controls. These findings led us to hypothesize that dysregulation of STIM1 and store operated calcium entry (SOCE) signaling may contribute to altered megakaryopoiesis and development of fibrosis in both SS and MPNs. To further delineate these processes, we analyzed samples from our two SS patients, demonstrating constitutive activation of SOCE causing increased calcium flux, as well as decreased aggregation in mature platelets. We also performed transmission electron microscopy (TEM) and identified platelets with abnormal granularity in dense and alpha granules. We also performed single cell RNA-seq on SS patient peripheral blood mononuclear cells, which revealed enhanced NFkB inflammatory signaling, suggesting that altered signaling driven by STIM1 mutations may drive aberrant inflammation to contribute to MF development. To corroborate these initial observations, we identified a separate family cohort of 9 individuals in Italy with SS and confirmed STIM1 mutation (L92V). In ex vivo megakaryocytic differentiation assays, cells derived from these patients demonstrated a defect in thrombopoiesis with significantly decreased pro-platelet formation and adhesion to extracellular matrix. To further characterize the effects of the gain of function STIM1 mutations seen in our patients, we developed a novel, conditional knock-in mouse model of the heterozygous R304W mutation in the coiled coil (CC) domain of Stim1. Induction of hematopoietic-specific expression of mutant Stim1 via Vav-Cre resulted in recapitulation of hematological features of SS, including thrombocytopenia and a mild bleeding tendency, with confirmation of increased SOCE activity and calcium flux. Notably, we confirmed the development of bone marrow fibrosis, as well as findings of severe osteosclerosis, in these mice. TEM imaging confirmed that platelets from Stim1R304W/+Vav-Cre mice exhibit abnormal granularity, similar to what we observed from our SS patients. Noting that we identified increased STIM1 expression in samples from MPN patients harboring either JAK2 or CALR mutations, we further characterized the role of STIM1 in MPN disease development. NSGS mice were engrafted with CALR-mutant CD34+ cells subjected to CRISPR ablation of STIM1. Recipient mice exhibited decreased human CD45+ cell engraftment in conjunction with prolonged survival. In contrast, targeting of STIM1 in JAK2-mutant CD34+ cells led to exacerbated disease phenotypes, as manifested by enhanced human CD45+ cell engraftment, worsened splenomegaly, and early lethality. Taken together, these findings suggest a striking, differential relationship between mutant JAK2 and CALR and STIM1 activity and their relationship to MF development. Altogether, this study represents the first demonstration of MF development in patients with Stormorken Syndrome, and reveals a previously unrecognized hallmark of altered calcium signaling via aberrant STIM1 activation underlying SS and MPNs. We further demonstrate recapitulation of these hematologic features in a novel knock-in Stim1R304W/+Vav-Cre mouse model. These findings implicate an important role for STIM1and SOCE activity in MF development, and further uncover important distinctions between JAK2 vs CALR mutations and their interaction with altered STIM1 activity. These studies may contribute to the development of novel therapeutic approaches for these disorders.
The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
Hu, Guangzhen , Dasari, Surendra , Gimenez, J. , Salama, Farah M., Chan, Wing C. , Cook, James R. , Inghirami, Giorgio , Rosenwald, Andreas , Staudt, Louis M. , Wright, George W. , Amador, Catalina, Greiner, Timothy C. , Ondrejka, Sarah L. , Ott, German , Slack, Graham W. , Aljudi, Ahmed, Ansell, Stephen M. , Chapman‐Fredricks, Jennifer R., Chen, Weina , Gru, Alejandro A. , Jiang, Liuyan , Ko, Young Hyeh , Anamarija, Perry M., Satou, Akira , Wu, Xiaojun , Yoshino, Tadashi, Zeng, Yu , Gru, Alejandro , Wright, George , Feldman, Andrew L. , Rimsza, Lisa M. , Scott, David W. , Gimenez, Jimena B., Salama, Farah M., Shi, Min , Campo, Elı́as , Jaffe, Elaine S. , Morin, Ryan D , Raess, Philipp W. , Savage, Kerry J. , Delabie, Jan , Iqbal, Javeed , Hilton, Laura K. , Pittaluga, Stefania , Slager, Susan L. , Song, Joo Y. , Wang, Hao‐Wei , Barrionuevo, Carlos , Cerhan, James R. , Leval, Laurence de , Jaye, David L. , Kahl, Brad S. , Karube, Kennosuke , Mou, Eric , Maurer, Matthew J. , Medeiros, L. Jeffrey , Miranda, Roberto N. , Oishi, Naoki , Wang, Xueju , Wilcox, Ryan A.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2974-2974

10.1182/blood-2024-202410 Get It

Background: Anaplastic large cell lymphomas (ALCLs) represent a heterogeneous group of T-cell lymphomas that currently are classified by the presence or absence of ALK tyrosine kinase (TK) fusion genes (ALK+ or ALK−) and clinical presentation (systemic, cutaneous, or breast implant-associated). Two overarching molecular types of ALCL recently were discovered, defined by the presence (Type I) or absence (Type II) of a gene expression signature highly enriched for JAK-STAT3 activation. Fusions involving non-ALK TK genes occur in some ALK− cases, but the fusion landscape of ALCL remains incompletely characterized. Methods: Expert consensus pathology review was conducted in the Lymphoma/Leukemia Molecular Profiling Project (LLMPP). RNAseq was performed and fusions were identified using FusionCatcher. Here, we focused on recurrent in-frame coding fusions. Previously unreported fusions were validated by RT-PCR. Type I/II was assigned using a previously validated gene expression-based model. Genes with adjusted (adj) P<0.05 were considered differentially expressed. Overall survival (OS) was assessed for systemic ALCL, when available. Results: We evaluated 379 ALCLs (229M/150F; mean age, 56 y). Of 199 candidate fusions (excluding reciprocal events), 28 were recurrent and passed quality metrics. At least 1 of these 28 fusions was present in 150 cases (40%). ALK fusions were present in 106 ALK+ ALCLs (all Type I; P<0.0001). Of these, NPM1::ALK was seen in 68/106 (64%). Alternate partners (X::ALK) included ATIC (N=24) and CTLC, COL1A2, MSN, MYH9, RNF213, SATB1, TFH, TPM3, and TRAF1 (1-3 cases each). X::ALK was associated with older age (mean, 52 y) than NPM1::ALK (32 y; P<0.0001) and showed relative overexpression of 49 genes, including multiple activators of small GTPases such as CGNL1 (FC, 5.6; Padj=2.4×10-6), SRGAP1, ALS2, DOCK1, and NCKAP1. ALK expression was similar in cases with NPM1::ALK and X::ALK and there was no significant difference in OS. Non-ALK TK fusions were seen in 17/273 ALK− cases (6%), including TYK2 (N=9); JAK2 (N=6); and ROS1 (N=2). All were Type I ALCLs (P<0.0001). ALK− cases with non-ALK TK fusions overexpressed 38 genes compared to ALK− cases without TK fusions, including cytokines involved in the IL17 signaling pathway such as CXCL6 (FC, 12.5; Padj=4.2×10-3), CXCL1, and CSF3. We then assessed the relationship between ALK− cases with non-ALK TK fusions and ALK+ cases by separately comparing each subset to ALK− cases without TK fusions. FC values for ALK− cases with non-ALK TK fusions were significantly correlated with FC values for ALK+ ALCLs over the set of expressed genes (R=0.54; P<0.0001). At a median follow-up of 32 months, 0/4 systemic ALCL patients with non-ALK TK fusions had died, while 30% of those with ALK− ALCL without TK fusions had died, but this was not statistically significant (P=0.26). The other 13 ALK− cases with non-ALK TK fusions were either localized ALCLs or did not have outcome data available. Of 20 TP63 fusions, 17 (85%) were TBL1XR1::TP63 and 3 were X::TP63. As previously reported, TP63 fusions were associated with poor OS (median OS, 10 months; not reached for other ALK− ALCLs; P=0.007). Four ALCLs had a novel NCL::UBTF fusion involving genes encoding the nucleolar proteins nucleolin and nucleolar (upstream binding) transcription factor-1. Four cases each had PARG::BMS1 and TNK1::GPS2 (the latter seen only in Type I ALCLs). Conclusions: This large consortium-based analysis of coding fusions further elucidates the molecular distinction between Type I and Type II ALCLs. Both ALK and non-ALK TK fusions were seen exclusively in Type I ALCLs, which we have shown previously are enriched for JAK-STAT3 pathway genes and correlate strongly with pSTAT3Y705 positivity by immunohistochemistry. These fusions were not identified in Type II ALCLs, which previous data suggest are associated with epigenetic alterations. ALK+ ALCLs with NPM1::ALK and X::ALK showed differences in gene expression, suggesting biological differences. Furthermore, ALCLs with non-ALK TK fusions shared gene expression features with ALK+ ALCL. Clinical fusion detection could enhance molecular classification of Type I and Type II ALCLs and may guide precision therapy.
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
Jeyakumar, Nikeshan , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Boccucci, Jacob , Ulrickson, Matthew L. , Vasu, Sumithira, Langston, Amelia , Kopmar, Noam E. , Tsai, Stephanie B., O’Connor, Timothy E. , Park, Jae H. , Valtis, Yannis K. , Solh, Melhem , Dekker, Simone E. , Malik, Shahbaz A. , Shaughnessy, Paul , Mountjoy, Luke , Hoeg, Rasmus T. , Oliai, Caspian , Gupta, Vishal , Koura, Divya, Kumaran, Muthu V., Schwartz, Marc S. , Tracy, Sean , O'Dwyer, Kristen M., Moore, Jozal , Bobillo, María Silvina Odstrcil , Frey, Noelle, Connor, Matthew P. , Ladha, Abdullah , Yaghmour, George , Gatell, Vivian Irrizary, Pullarkat, Vinod , Merchant, Akil, Muffly, Lori , Muffly, Lori , Muhsen, Ibrahim N. , Advani, Anjali S. , Roloff, Gregory W. , Grunwald, Michael R. , Kota, Vamsi , Sasine, Joshua , Aldoss, Ibrahim , Othman, Tamer , Vasu, Sumithira , Reshef, Ran , Luskin, Marlise R , Chen, Evan , Lin, Chenyu , Cassaday, Ryan D. , Tsai, Stephanie B., Hilal, Talal , Faramand, Rawan , Bezerra, Evandro D. , Leonard, Jessica T , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Oliai, Caspian H , Dykes, Kaitlyn C. , Logan, Aaron C , Stock, Wendy , Schwartz, Marc, Bachanová, Veronika , O'Dwyer, Kristin , Lee, Catherine J , Frey, Noelle, Jamy, Omer , Daunov, Michael , Jackson, Clayton, Gatell, Vivian Irizarry , Oluwole, Olalekan O. , Dholaria, Bhagirathbhai , Shah, Bijal , Hill, LaQuisa C.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 523-523

10.1182/blood-2024-210682 Get It

Introduction: Brexucabtagene Autoleucel (brexu-cel) is the first CD19-targeting chimeric antigen receptor (CD19.CAR) T-cell therapy approved for the treatment of relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) in adult (≥18 yo) patients (pts) based on results from the ZUMA-3 trial. However, data on the safety and efficacy of CAR-T cells in older pts (≥60 yo) remains limited, with only 8 pts >65 yo enrolled in the ZUMA-3 trial. We evaluated the treatment characteristics and outcomes with use of brexu-cel amongst patients ≥60 yo in the Real-World Outcomes Collaborative for CAR-T in ALL (ROCCA) consortium database. Methodology: ROCCA is a consortium of over 30 U.S.-based institutions with a database of adult pts with B-ALL who received brexu-cel as standard of care therapy. We identified pts ≥60 yo and further stratified them into two cohorts: 60-69 yo and ≥70 yo. Outcomes of interest included OS, PFS, ORR, and toxicities (CRS and ICANS). Both OS and PFS were calculated from the day of brexu-cel infusion. Response assessment occurred on day +28, and MRD evaluation was per institutional practices. CRS and ICANS were graded according to the American Society for Transplantation and Cellular Therapy criteria. Results: Of 280 brexu-cel recipients in the ROCCA database, 73 (26%) were ≥60 yo, of which 58 (79%) were between 60-69 yo and 15 (21%) were ≥70 yo. Among pts ≥60 yo, the median age at infusion was 65 (range 60-81). Pts were heavily pretreated with a median of 3 prior lines of therapy (range 2-9). Prior therapies included: allogeneic HSCT (38%), inotuzumab ozogamicin (41%), and blinatumomab (62%). Forty pts (55%) had Ph-negative B-ALL, 24 (33%) had Ph+ B-ALL and 9 (12%) had Ph-like B-ALL. When grouped by HCT-CI equal to 0, 1-2 or ≥3, a higher proportion of pts ≥60 yo had HCT-CI ≥3 (19% vs. 7% in <60 yo; p=0.004). Pre-apheresis, 33 pts (45%) had active disease (>5% marrow blasts or extramedullary disease), 34 (47%) were in CR (of whom 14 were MRD-negative) and 6 had unknown disease status. Following brexu-cel, 43 (59%) achieved MRD-negative CR, 20 (27%) had MRD + or CR with unknown MRD status, 6 (8%) had refractory disease and 5 had no disease evaluation available. The ORR was similar between pts 60-69 and ≥70 yo (MRD-negative CR rate: 58% vs 61%, r/r to brexu-cel: 9% vs 6%) and was comparable to pts <60 yo (MRD-negative CR 66%; r/r disease of 9%). The rate of all grade ICANS was higher in pts ≥70 (77%) than in pts 60-69 (47%) or pts <60 (49%), with grade 1-2 ICANS occurring at a significantly higher rate in pts ≥70 (44% vs. 20% in 60-69 and 20% in <60, p=0.049). Grade 3-4 ICANS were similar between the groups: 33%, 27% and 29% in the ≥70, 60-69, and <60 groups, respectively. Conversely, rates of CRS were similar across age groups (80-84%). There was no statistically significant difference in the rate of grade 3-4 CRS which was 17% in pts ≥70, 4% in pts 60-69, and 11% in pts <60 yo. With a median follow-up of 332 days (range 8-936 days) from infusion, pts ≥60 yo had a median PFS of 395 days compared to 547 days in pts <60 yo. Median PFS was lower in the ³70 yo (231 days) compared to 677 in the 60-69 yo cohort. No statistically significant difference was found between the <60 and ≥60groups in 6- and 12-month PFS rates (6 months PFS: 66% vs 64%, p=0.77 and 12 months PFS: 57% vs 57%, p=1.00). When pts ≥60 yo were stratified by age, pts ≥70 yo had similar 6-month PFS compared to other age groups but significantly lower 12-month PFS (38%; vs. 64% in pts 60-69and 57% in pts <60, p=0.001). Median OS was not reached in any of the age groups, and there was no statistically significant difference in 6-month OS (72% in ≥ 70 vs. 82% in the 60-69 vs. 82% in <60, p=0.14) or 12-months OS (61% in ≥ 70 vs. 69% in 60-69 vs. 73% in <60, p=0.18). Conclusion: This is the largest study to date of older B-ALL pts receiving CAR-T cells. We observed that older pts, particularly those aged 60-69, have similar outcomes to younger pts. However, pts ≥70 yo had lower median and 12-month PFS when compared to younger patients. Additionally, pts ≥70 yo had higher rates of grades 1-2 ICANS. An important limitation of this analysis is the potential selection bias among clinicians when selecting older patients for this treatment. Longer follow-up, including inclusion of additional pts ≥70 yo is needed to confirm these results, and further studies are needed to identify the optimal approach for use of CAR T-cell therapy in patients in this age group.
Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis
Chanan‐Khan, Asher , Khouri, Jack , Yannakou, Costas K. , Guo, Huanshan, Wang, Hengbang , Li, Mingyu , Yang, Dajun , Ailawadhi, Sikander , Chen, Zi , Wang, Yanyan , Ahmad, Mohammad , Zhai, Yifan

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1022-1022

10.1182/blood-2024-202713 Get It

Introduction MM is characterized by the proliferation of abnormal clonal plasma cells, causing destructive bone lesions, kidney injury, anemia, and hypercalcemia. Treatment of MM involves immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies to achieve disease remission. AL amyloidosis comprises disorders of abnormal extracellular deposition of misfolded proteins in various organs with resultant damage, and the key strategy of treatment is to prolong the time to or reverse organ dysfunction. However, many patients will relapse from the standard triplet or quadruplet therapies, necessitating additional treatments with novel mechanisms of action. Lisaftoclax is a novel investigational BCL-2 inhibitor with strong antitumor activity in hematologic malignancies. Here, we report clinical trial data on lisaftoclax combined with novel therapeutic regimens in pts with R/R MM or R/R AL amyloidosis. Methods Eligible patients had an ECOG performance status ≤ 2, ≥ 1 prior line of therapy, and adequate organ function. Patients with R/R AL amyloidosis had confirmed symptomatic organ involvement, purpura, and/or carpal tunnel syndrome. Lisaftoclax was administered orally daily at doses assigned in repeated 28-day cycles. Pomalidomide, daratumumab, and lenalidomide were administered per label use. Dexamethasone 40 mg (20 mg, pts > 75 years old) was administered on days 1, 8, 15, and 22 of 28-day cycles. This study evaluated the safety and efficacy of lisaftoclax combined with pomalidomide and dexamethasone (Pd; Arm A) or daratumumab, lenalidomide, and dexamethasone (DRd; Arm B) in R/R MM and lisaftoclax combined with Pd in R/R AL amyloidosis (Arm C). Intensive blood samples were collected for pharmacokinetic (PK) analyses. Results As of May 29, 2024, 52 pts were enrolled, including 42 with R/R MM and 10 with AL amyloidosis. In Arm A (n = 35), lisaftoclax was administered orally at dose assigned: 400 mg (n = 3), 600 mg (n = 4), 800 mg (n = 15), 1,000 mg (n = 7), and 1,200 mg (n = 6). In Arm B (n = 7), all pts were treated with lisaftoclax 600 mg. In Arm C (n = 10), lisaftoclax was administered at 400 mg (n = 1), 600 mg (n = 4), 800 mg (n = 3), and 1,000 mg (n = 2). The median (range) age of all patients was 69.5 (24-88) years, of whom 63.5% were male and 63.5% were ≥ 65 years of age. The enrolled patients were heavily treated, with a median (range) number of treatment cycles of 4 (1-26), and a median (range) number of prior therapy lines of 3 (1-19). In Arm A, out of 31 evaluable patients, 3 (9.7%) achieved complete remission (CR), 7 (22.6%) reached very good partial remission (VGPR), and 9 (29.0%) achieved partial response (PR). The overall response rate (ORR) was 19 (61.3%), and the ≥ VGPR rate was 10 (32.3%). In Arm B, of 4 evaluable patients, 2 (50%) achieved CR and 2 (50%) ≥ VGPR. In Arm C, of 7 assessed patients, 1 (14.3%) achieved CR, 4 (57.1%) VGPR, 1 (14.3%) PR, and 5 (71.4%) ≥ VGPR, for an ORR of 6 (85.7%); 2 pts had cardiac response. Among 49 pts in the safety population, 34 (69.4%) reported any-grade lisaftoclax treatment-related AEs (TRAEs; ≥ 5% incidence), including neutropenia (20.4%), thrombocytopenia (6.1%), leukopenia (10.2%), nausea (16.3%), abdominal distension (10.2%), diarrhea (12.2%), and constipation (8.2%). A total of 11 pts experienced grade ≥ 3 TRAEs, including neutropenia (14.3%) and febrile neutropenia (2%), and 3 pts experienced lisaftoclax-related serious AEs (1 each): febrile neutropenia, acute kidney injury, and diarrhea with electrolyte imbalance. In Arm B, 1 pt experienced a dose-limiting toxicity (prolonged QT interval). Pharmacokinetic analyses showed no drug-drug interaction (DDI) in all pts treated with lisaftoclax at all doses in combination with other therapeutic agents used in 3 arms. Conclusions Our findings suggest that lisaftoclax improves the depth of response in pts with R/R MM or AL amyloidosis when combined with Pd or DRd. These combination therapies demonstrated a favorable safety profile with no drug-drug interactions, particularly in hematologic side effects. ClinicalTrials.gov registration: NCT04942067; internal study identifier: APG2575MU101.